We're here to help you with patient support, reimbursement assistance, and access solutions for EYLEA

Use our wide range of resources to help your patients access EYLEA and address any questions you might have.

EYLEA4U® logo.

ICD-10 code finder

Use the interactive code finder to quickly find the current ICD-10 codes for the anti-VEGF agent EYLEA. To begin, simply answer the following short questions.

The coding information discussed here is provided for informational purposes only, is subject to change, and should not be construed as legal advice. The codes listed here may not apply to all patients or to all health plans; providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

For which indication is EYLEA being administered?

  • Wet Age-related Macular Degeneration (Wet AMD)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
  • Macular Edema following Central Retinal Vein Occlusion (MEfCRVO)
  • Macular Edema following Branch Retinal Vein Occlusion (MEfBRVO)
{{DownloadFormModel.OutputFileName}}.zip  {{DownloadFormModel.DownloadSize}} MB

We are here for you in person, online, or by phone

Your office has a dedicated Reimbursement Business Manager and Medical Specialist who are always available for in-office support.

Call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248) Monday–Friday 9 AM–8 PM Eastern Time.

  1. Healthcare provider medical
    information inquiries
  2. Patient or caregiver medical
    information inquiries

  3. Adverse events,
    product complaints,
    and product returns

  4. Reimbursement and patient
    assistance support
  5. Product-ordering
    assistance through
    one of our distributors
EYLEA4U® logo.

EYLEA4U e-Portal: Your one-stop, online destination for reimbursement and patient support

The EYLEA4U e-Portal is an efficient, secure, and convenient tool for enrolling and managing patients in our support programs. The portal is available online for instant access to patient case status updates.*

  • *Requires registration and e-signature setup.

Product support

EYLEA® (aflibercept) pre-filled syringe and packaging.

With EYLEA comes complete product support. Find all the information you need for ordering EYLEA, requesting a return, getting a discount, and more—and EYLEA4U is available to guide you through it.

Support for the reimbursement process.

Navigating reimbursement

EYLEA4U is here to help you through the entire reimbursement process. Easily download enrollment forms, learn about prior authorization requirements, and more.

Start the process

Patient Support

EYLEA4U is committed to help ensure your eligible patients have access to anti-VEGF agent EYLEA for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (MEfRVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Our programs include*:

Copay card program for EYLEA cost assistance.
EYLEA Copay Card Program

With the EYLEA Copay Card, patients with commercial healthcare coverage may be eligible to pay as little as a $0 copay for each EYLEA injection cost.†,‡ Subject to annual assistance limit.

See the program
Eligible patients can receive EYLEA at no cost.
Patient Assistance Program

No insurance or no coverage for EYLEA? No problem. The Patient Assistance Program (PAP) from EYLEA4U can provide EYLEA free of charge to eligible patients.II

Get more information
Alternate Coverage Referral process information.
Alternate Coverage Referral

EYLEA4U can provide
information about the referral process, which connects patients in need to independent charitable foundations.§

Learn about the process
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

  1. Data on file. Regeneron Pharmaceuticals, Inc.